Replies to post #97915 on Biotech Values

[DewDiligence]

The discussion of SNY in the Barron’s piece contains a glaring omission!

[jbog]

Turtle,

"In all, the top nine players are spending some $50 billion a year on research and development, and at least some of those investments could pay off handsomely."

What a waste of money. I don't see anyway they could recoup the $250 bil that has been spent over the last 5 years.

[DewDiligence]

[Barron’s]: “[PFE has] some drugs in its pipeline that could prove to be important, including treatments for rheumatoid arthritis and lung cancer.”

[turtlepower]: Obviously, Barron’s is not up to date

Barron’s is indeed up to date. You may have been confusing Tanezumab , PFE’s NGF mAb for osteoarthritis (which was put on clinical hold by the FDA in June: #msg-51634760) with CP-690,550, PFE’s JAK3 inhibitor for RA, which is very much alive.

[DewDiligence]

(5-year lookback)—This Barron’s piece from 2010 on the low valuations of Big Pharma was spot-on; almost all of them have had huge runs since then:

#msg-51734762